Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Celtic Therapeutics Rebrands as Auven Therapeutics

Published: Tuesday, July 30, 2013
Last Updated: Tuesday, July 30, 2013
Bookmark and Share
Company’s name change effective from March 11, 2013.

Celtic Therapeutics Management L.L.L.P. (Celtic Therapeutics) has announced a name change to Auven Therapeutics Management L.L.L.P (Auven Therapeutics) effective from March 11, 2013.

The name change was made in order to overcome confusion related to other Celtic entities, which are not part of Auven Therapeutics.

Auven Therapeutics’ rebrand reflects the Company’s mission to provide the gold (Au) standard in drug (Ven) development, progressing promising therapeutic pharmaceutical candidates in areas of unmet medical need.

Auven Therapeutics was founded by Dr. Peter B. Corr and Stephen Evans-Freke in 2007 and is pursuing an innovative investment strategy - while it is structured as a private equity fund, it also operates as a drug development company.

Commenting on the new name and the strategy of the fund, co-founder and co-Managing General Partner Stephen Evans-Freke said: “Capitalizing on the wealth of expertise of our development team, we take ownership and control of the development of carefully selected clinical-stage therapeutic assets in order to build value around them to the point where they are attractive acquisition opportunities for established pharmaceutical and biotechnology companies.”

Auven Therapeutics has a portfolio of biologic and small molecule therapeutic candidates, primarily comprising preclinical to mid-stage development programs, for a wide range of therapeutic indications including cancer, ophthalmic conditions, women’s health and orphan diseases.

It has ownership of or a majority interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals.

Dr. Peter B. Corr, co-founder and co-Managing General Partner added: “We are excited about our portfolio of innovative therapeutic assets. In particular, our investments in Spirogen and ADC Therapeutics have great potential to develop new and much more effective treatments for a variety of cancers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos